Abstract
The goal of this paper was to examine the literature related to stromal cell-derived factor 1-alpha (SDF-1alpha) and its receptor CXCR4 in endometrial cancer, as expression of these biomarkers has been implicated in an aggressive phenotype in other common epithelial cancers. We conducted a qualitative review of all published studies examining the role of SDF-1alpha/CXCR4 in endometrial cancer progression and prognosis. Pubmed and Ovid MEDLINE databases were searched in order to identify relevant studies for this qualitative review. Four studies have examined the role of the SDF-1alpha/CXCR4 pathway on endometrial cancer progression. The findings were contradictory; two studies reported an inverse association between overexpression and mortality while two studies reported overexpression to be associated with hallmarks of aggressive endometrial cancer. Expression of stromal-derived proteins can potentially serve as biomarkers of aggressive disease as well as biomarkers for remission monitoring, however the endometrial cancer literature has lagged behind in this area. Furthermore, the current research suffers from lack of comparability among different studies due to the utilization of different tools and lack of common outcome definitions. Future studies in this area should use clinically meaningful protein expression categories, widely accepted outcome definitions, and larger samples of patients. Finally, although standard immunohistochemistry is a mainstay in tumor marker studies, automated detection methods may be more suitable as they do not rely on subjective interpretation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sohaib SA et al (2007) Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 62(1):28–34, discussion 35–6
Amant F et al (2005) Endometrial cancer. Lancet 366(9484):491–505
Itano N, Zhuo L, Kimata K (2008) Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 99(9):1720–1725
Shiozawa T, Konishi I (2006) Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol 11(1):13–21
Balkwill F (2004) Cancer and the chemokine network. Nat Rev, Cancer 4(7):540–550
Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14(3):181–185
Hall JM, Korach KS (2003) Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17(5):792–803
Scotton CJ et al (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62(20):5930–5938
Hwang JH et al (2003) CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88(1):408–416
Zhao D et al (2006) Stromal cell-derived factor 1alpha stimulates human endometrial carcinoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt. Gynecol Oncol 103(3):932–937
Li XP et al (2006) Growth and activation of PI-3K/PKB and Akt by stromal cell-derived factor 1alpha in endometrial carcinoma cells with expression of suppressor endoprotein PTEN. Chin Med J (Engl) 119(5):378–383
Mizokami Y et al (2004) Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. Int J Cancer 110(5):652–659
Kodama J et al (2007) Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol 28(5):370–375
Tsukamoto H et al (2007) Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clin Exp Metastasis 24(6):423–429
Gelmini S et al (2009) The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 26(3):261–268
Kodama J et al (2007) Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 18(2):269–274
Burns JM et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9):2201–2213
McCabe A et al (2005) Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97(24):1808–1815
Henson DE (2005) Back to the drawing board on immunohistochemistry and predictive factors. J Natl Cancer Inst 97(24):1796–1797
Cregger M, Berger AJ, Rimm DL (2006) Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 130(7):1026–1030
Zhang S et al (2008) Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 27:62
Kajiyama H et al (2008) Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122(1):91–99
Mirisola V et al (2009) CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 45(14):2579–2587
Liu F et al (2009) Increased expression of SDF-1/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast. Histopathology 54(6):741–750
Acknowledgements
This research was supported by a National Institutes of Health grant R25-CA57703.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Felix, A.S., Edwards, R., Bowser, R. et al. Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer. Cancer Microenvironment 3, 49–56 (2010). https://doi.org/10.1007/s12307-010-0042-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12307-010-0042-7